These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9549956)

  • 1. An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder.
    Malhotra S; Santosh PJ
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):364-71. PubMed ID: 9549956
    [No Abstract]   [Full Text] [Related]  

  • 2. An open trial of buspirone in the treatment of attention-deficit disorder.
    Niederhofer H
    Hum Psychopharmacol; 2003 Aug; 18(6):489-92. PubMed ID: 12923830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buspirone in ADHD with ODD.
    Gross MD
    J Am Acad Child Adolesc Psychiatry; 1995 Oct; 34(10):1260. PubMed ID: 7592261
    [No Abstract]   [Full Text] [Related]  

  • 4. Buspirone in ODD.
    Dunne JE
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):942. PubMed ID: 10434482
    [No Abstract]   [Full Text] [Related]  

  • 5. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample.
    Waring ME; Lapane KL
    Pediatrics; 2008 Jul; 122(1):e1-6. PubMed ID: 18595954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive association between attention-deficit/ hyperactivity disorder medication use and academic achievement during elementary school.
    Scheffler RM; Brown TT; Fulton BD; Hinshaw SP; Levine P; Stone S
    Pediatrics; 2009 May; 123(5):1273-9. PubMed ID: 19403491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children.
    Mosholder AD; Gelperin K; Hammad TA; Phelan K; Johann-Liang R
    Pediatrics; 2009 Feb; 123(2):611-6. PubMed ID: 19171629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buspirone for attention deficit hyperactivity disorder?
    Balon R
    J Clin Psychopharmacol; 1990 Feb; 10(1):77. PubMed ID: 2307742
    [No Abstract]   [Full Text] [Related]  

  • 9. Desipramine in the treatment of children with attention deficit disorder.
    Biederman J; Gastfriend DR; Jellinek MS
    J Clin Psychopharmacol; 1986 Dec; 6(6):359-63. PubMed ID: 3805329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of buspirone and bupropion in the treatment of depression.
    Fava M
    Psychother Psychosom; 2007; 76(5):311-2. PubMed ID: 17700052
    [No Abstract]   [Full Text] [Related]  

  • 13. Attention-deficit/hyperactivity-related symptoms among children with enterovirus 71 infection of the central nervous system.
    Gau SS; Chang LY; Huang LM; Fan TY; Wu YY; Lin TY
    Pediatrics; 2008 Aug; 122(2):e452-8. PubMed ID: 18606624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone and serotonin in spinocerebellar ataxia.
    Gazulla J; Modrego P
    J Neurol Sci; 2008 May; 268(1-2):199-200; author reply 200-1. PubMed ID: 18222483
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN; Lesesne CA; Perou R
    Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does connection to primary care matter for children with attention-deficit/hyperactivity disorder?
    Toomey SL; Finkelstein J; Kuhlthau K
    Pediatrics; 2008 Aug; 122(2):368-74. PubMed ID: 18676555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design.
    Megna J; O'dell M
    Arch Phys Med Rehabil; 2001 Aug; 82(8):1145-8. PubMed ID: 11494197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.